Physician profile
Jiantao Ding
NPI 1396764551
$4,439.27
in general payments reported to CMS, 2019-2025
36 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $14.87 · 2021: $143 · 2022: $1,154 · 2023: $481 · 2024: $935 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.02 |
| Education | $168.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,357.21 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| E.R. Squibb & Sons, L.L.C. | $373.17 | 2021-2025 | Reblozyl, Opdivo, Opdualag |
| Celgene Corporation | $259.13 | 2023-2025 | Reblozyl, Pomalyst |
| Eisai INC. | $253.58 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $221.91 | 2023-2025 | Enhertu, Imfinzi |
| Gilead Sciences, INC. | $217.27 | 2021-2025 | Trodelvy |
| Pfizer INC. | $135.78 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $130.80 | 2024 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $123.00 | 2025 | Orserdu |
| Incyte Corporation | $122.17 | 2025 | Monjuvi, Jakafi |
| Lilly USA, LLC | $110.50 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $103.76 | 2022-2025 | |
| Abbvie INC. | $101.61 | 2023-2025 | Venclexta |
| Tempus Ai, INC | $93.07 | 2024 | |
| Epizyme, INC. | $91.91 | 2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiantao Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.